Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community

ARDX 10.21.2024

Full Press ReleaseSEC FilingsOur ARDX Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
  • 01.06.2025 - Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - 8-K Current report
Deadline to submit nominations is January 31, 2025

WALTHAM, Mass.,Oct. 21, 2024(GLOBE NEWSWIRE) --Ardelyx, Inc.(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of theDerek Forfang Patient AdvocateAward to recognize passionate supporters of patients living with chronic kidney disease (CKD) who champion the need for innovation and improved health outcomes for patients. This award was established to honor Derek Forfang, an amazing person who suffered from chronic kidney disease and passed away due to issues related to his disease in 2023. Derek was the inspiration and founding member of theArdelyx Patient Advisory Council, which was just one of the many committees to which Derek belonged. Derek worked tirelessly to improve the lives of patients, families and caregivers in the CKD community. This award serves to recognize individuals who, like Derek, raise awareness of the challenges that kidney patients face, are willing to be the voice for their community and deserve to be recognized for their contributions.

“There are so many individuals, patients, family members and caregivers, who are making incredible efforts to advocate for patients with chronic kidney disease,” saidAlan Ryan, DEdMin, Senior Director of Patient Advocacy atArdelyx. “At Ardelyx, we believe that it is critical to support, celebrate and advance those voices and believe there is no better way to do that than to continue the legacy of our friend and partner, Derek Forfang. There are so many people who are deserving of this recognition, and we encourage everyone in the community to submit a nomination.”

Ardelyxis now accepting nominations for theDerek Forfang Patient AdvocateAward. Candidates for the award can be nominated by anyone in the community at large and are considered for the award by theDerek Forfang Patient Advisory Council(DFPAC). To be eligible for the award, nominees must demonstrate achievements and contributions to advocate for CKD patients, which could include raising awareness, educating others, advancing research, advocating for the community and bringing the community together, among many other efforts. Recipients of theDerek Forfang Patient AdvocateAward will receive a$1,000honorarium and a$4,000donation to be made to a non-profit organization supporting the CKD community.

Nominations can be submitted online athttp://ardelyx.com/DFPAAward. The deadline for nominations isJanuary 31, 2025. Full Terms and Conditions for the award can be found athttp://ardelyx.com/DFPAAward.

AboutArdelyxArdelyxwas founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs.Ardelyxhas two commercial products approved inthe United States, IBSRELA®(tenapanor) and XPHOZAH®(tenapanor).Ardelyxhas agreements for the development and commercialization of tenapanor outside of theU.S.Kyowa Kirin commercializes PHOZEVEL®(tenapanor) for hyperphosphatemia inJapan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted inChinawith Fosun Pharma. Knight Therapeutics commercializes IBSRELA inCanada. For more information, please visithttps://ardelyx.com/and connect with us onX (formerly known as Twitter),LinkedInandFacebook.

Investor and Media Contact:Caitlin Lowieclowie@ardelyx.com

Primary Logo

Source: Ardelyx, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com